EZH2-IN-4 biochemical

EZH2-IN-4

CATALOG #
AAA228088


PRODUCT SYNONYMS

EZH2-IN-4; EZH2-IN-4 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2088132-99-2
Targets&IC50	mut 5-mer EZH2:2.65 nM (IC50), WT 5-mer EZH2:0.923 nM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	EZH2-IN-4 (example 38; oral gavage; 15 mpk; BID) results in 73% inhibition of tumor methylation in the Karpas-422 xenograft model[1]. EZH2-IN-4 (po; 50 mpk; twice a day; pretreatment for 5 days; followed by co-administration with gemcitabine plus cisplatin for at least 23 additional days) significant inhibits A2780 tumor growth in A2780 xenograft model[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
32-Carbonyl)-RMC-5552, CAS 2382768-55-8



Structure
32-Carbonyl)-RMC-5552, CAS 2382768-55-8

ADDITIONAL INFORMATION

Related Product Information for EZH2-IN-4 biochemical	EZH2-IN-4 is an orally active, potent EZH2 inhibitor with IC 50 s of 0.923 nM and 2.65 nM against wild type (WT) 5-membered (5-mer) EZH2 and mutant 5-mer EZH2, respectively. EZH2-IN-4 has anti-cancer activity.
References	1. Jennifer PITZEN, et al. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors. WO2019212990A1.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.